Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 6/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15318518 | 0.90 | PTGS1 (0.52) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL859001 | 0.88 | PTGS1 (0.49) | PTGS1GSTK1GLO1NOD1 | |
| SCHEMBL858563 | 0.87 | PTGS1 (0.48) | PTGS1GSTK1GLO1 | |
| SCHEMBL20856994 | 0.87 | PTGS1 (0.48) | PTGS1GSTK1GLO1 | |
| SCHEMBL8214588 | 0.84 | KDM4E (0.38) | PTGS1GSTK1GLO1 | |
| SCHEMBL5426903 | 0.82 | PTGS1 (0.56) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL11871240 | 0.82 | PTGS1 (0.56) | PTGS1GSTK1GLO1NOD1LTA4H | |
| SCHEMBL5426926 | 0.82 | PTGS1 (0.56) | PTGS1GSTK1GLO1LTA4H | |
| SCHEMBL11871268 | 0.82 | PTGS1 (0.56) | PTGS1GSTK1GLO1NOD1LTA4H | |
| SCHEMBL859160 | 0.82 | PTGS1 (0.51) | PTGS1GSTK1GLO1NOD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103104-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2008030891-A2 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103208-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY PARP INHIBITORS AND METHODS OF TREATMENT THEREOF | PARP2, PARP12, PARP3 | PTGS1 198/4885GSTK1 1100/4885GLO1 2299/4885 |
| US-20080103104-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | PTGS1 1042/4885GSTK1 917/4885GLO1 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.